Natco Pharma Limited

Natco Pharma Limited

Natco Pharma Limited has launched Carboplatin Injection, a generic version of Paraplatin, in the U.S. market, addressing a critical shortage of the product.

Natco Pharma Limited

Natco Pharma Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026, confirming the dematerialization of securities and updating the records of the company.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange about the publication of newspaper notices regarding a forthcoming rights issue. The notices were published in Financial Express, Surya, and Janasatta on October 7, 2026. The publications are available on the company's website.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window will remain closed from October 1, 2026 to 48 hours after the declaration of the Unaudited Financial Results for the quarter ending September 30, 2026.

Natco Pharma Limited

Natco Pharma Limited has submitted the Exchange a copy Srutinizers report of 43rd Annual General Meeting held on September 30, 2026, and informed the Exchange regarding voting results.

Natco Pharma Limited

Natco Pharma Limited has held its 43rd Annual General Meeting (AGM) on September 30, 2026, where various items of business were considered, including the adoption of audited annual financial statements, confirmation of interim dividends, re-appointment of a director, and approval of raising funds through various methods.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange regarding Outcome of Fund Raising Committee Meeting approving the Letter of Offer for Rights Issue.

Natco Pharma Limited

Natco Pharma Limited has increased its investment in eGenesis, Inc. from US$14.00 million to US$16.70 million through its wholly owned subsidiaries. eGenesis is a biotechnology company focused on using its multiplex gene editing and genome engineering platform to transform solid organ and therapeutic cell transplantation for the treatment of serious diseases.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange about the Record Date for Rights Issue, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Natco Pharma Limited

Natco Pharma Limited has announced the record date for its rights issue as October 1, 2026, as per Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange about issue of securities on rights basis, with the Board of Directors approving the issuance of equity shares for an amount not exceeding ₹12,79,35,61,500/- by way of a rights issue to eligible equity shareholders.

Natco Pharma Limited

Natco Pharma Limited has announced a rights issue to eligible equity shareholders in the ratio of 2:21, with an issue price of ₹750 per share. The rights issue is to raise ₹12,79,35,61,500 for an amount not exceeding ₹12,79,35,61,500. The record date is October 1, 2026, and the rights issue period is from October 12 to October 22, 2026.

Natco Pharma Limited

Natco Pharma Limited has received in-principle approval from the National Stock Exchange of India Limited and BSE Limited for its Rights Issue of fully paid-up equity shares.

Natco Pharma Limited

Natco Pharma Limited has announced a draft letter of offer for a proposed rights issue of up to ₹13,000 million, with eligible equity shareholders entitled to subscribe to the issue in the ratio of [●] rights equity shares for every [●] fully paid-up equity share held on the record date. The issue price is ₹[●] per rights equity share, including a premium of ₹[●] per rights equity share. The company has received in-principle approvals from NSE and BSE for listing the rights equity shares.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 09, 2026. The Board has approved the issuance of fully paid up equity shares of the Company of face value of ₹2 each for an amount not exceeding ₹1,300 crore by way of a rights issue to the eligible equity shareholders of the Company. The Board has also constituted the Fund-Raising Committee and updated on the Scheme of Arrangement (Demerger) between Natco Pharma Limited and Natco Crop Health Sciences Limited.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding the 43rd Annual General Meeting of the Company for the year ended 31st March, 2026.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026, to consider and approve various business items, including raising of funds, adoption of audited annual financial statements, and re-appointment of a director.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange about the schedule of an investor meeting on September 7, 2026, in Hyderabad, organized by Antique Stock Broking and group.

Natco Pharma Limited

Natco Pharma Limited has invested US$ 14 million in eGenesis, Inc. through convertible promissory notes, taking its total investment in the biotechnology company to US$ 22 million.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange about a schedule of investor meetings to be held on August 27th and 28th, 2026, where company officials will discuss the latest investor presentation available on the company's website.